Ongoing Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Protect Your Rights - Contact Levi & Korsinsky

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is under investigation for potential violations of federal securities laws following the failure of its Phase III studies to meet primary endpoints related to fracture rate reduction [1][2]. Group 1: Study Results - The Phase III studies, Orbit and Cosmic, did not achieve their primary endpoint of reducing annualized clinical fracture rates compared to placebo and standard care, respectively [2][3]. - Despite showing improvements in bone density, the studies failed to correlate these results with a reduction in fracture rates [3]. Group 2: Company Response and Analyst Reactions - In response to the study results, Ultragenyx management cited a "low fracture rate in the placebo group" as a reason for the failed outcomes, claiming no "uncontrolled factors" were present in the study design [4]. - Following the announcement, analysts became cautious, with Barclays indicating limited opportunity for drug approval despite some clinical benefits observed [4].